ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0264

Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus
Abstract Number: 0265

Evaluation of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus as a Measure of Systemic Lupus Erythematosus (SLE) Disease Activity from the Clinician and the Patient Perspective: Experience from an Italian Cohort
Abstract Number: 0266

The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus
Abstract Number: 0267

Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
Abstract Number: 0268

Impact of Flares on Healthcare Resource Usage and PROs in Systemic Lupus Erythematosus Patients
Abstract Number: 0269

Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality
Abstract Number: 0270

The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE
Abstract Number: 0271

External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus
Abstract Number: 0272

Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold
Abstract Number: 0273

Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia
Abstract Number: 0274

The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades
Abstract Number: 0275

Paradoxical Relationship Between Disease Activity and Satisfaction with Care in Lupus
Abstract Number: 0276

Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy
Abstract Number: 0277

Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria
Abstract Number: 0278

Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].